SCHEMBL2837248

SCHEMBL2837248

Cc1c(C#N)sc2nc(-c3ccccc3)[nH]c(=O)c12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.61
KDM4E B2RXH2 6/20 0.61
HPGD P15428 6/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
HSD17B10 Q99714 2/20 0.50
TSHR P16473 1/20 0.50
CHEK1 O14757 1/20 0.50
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
POLB P06746 1/20 0.49
TMIGD3 P0DMS9 1/20 0.48
ADORA1 P30542 1/20 0.48
HTT P42858 3/20 0.47
ATM Q13315 1/20 0.47
GAA P10253 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2843704 0.90 KDM4E (0.50) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL2838028 0.89 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL2843024 0.88 TMIGD3 (0.46) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL2839683 0.85 CDKN1A (0.56) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL13475914 0.85 TMIGD3 (0.45) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL2837355 0.84 BRD4 (0.55) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL2837954 0.83 TNKS (0.47) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL13475911 0.82 TNKS (0.49) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL2836379 0.81 RXFP1 (0.59) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL2833833 0.80 FGFR1 (0.52) ALDH1A1KDM4EHPGDSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662814-B2 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases LABORATORIOS ALMIRALL, S.A. (ES) 2010-02-16 US disclosed
US-7662814-B2 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases LABORATORIOS ALMIRALL, S.A. (ES) 2010-02-16 US disclosed
EP-1590352-B1 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS ALMIRALL LAB (ES) 2007-06-27 EP disclosed
US-20060229306-A1 4-Aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as pde7 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-10-12 US disclosed
EP-1590352-A1 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2005-11-02 EP disclosed
WO-2004065391-A1 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS ALMIRALL PRODESFARMA S.A. (ES) 2004-08-05 WO disclosed
WO-2004065391-A1 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS ALMIRALL PRODESFARMA S.A. (ES) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229306-A1 4-Aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as pde7 inhibitors PDE7B, PDE7A, PDE3A ALDH1A1 374/4885KDM4E 2683/4885HPGD 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.